Orthocell has announced that it has successfully completed the first stage of the Remplir™ US 510(k) market authorisation nerve repair study.
Proactive | Interview with CEO Paul Anderson
Orthocell CEO Paul Anderson spoke with Proactive about the Company’s recent strategic placement of $3.5 million, adding prominent investors to the share register.
The West Australian | Chris Ellison, Rod Jones and the McCuskers jump into Orthocell
Orthocell’s Company-led strategic placement has been reported in The West Australian newspaper today, in an article by Senior Business Report Sean Smith titled “Chris Ellison, Rod Jones and the McCuskers jump into Orthocell”.
Orthocell Completes $3.5M Strategic Placement
Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million.
Orthocell submits Singapore Regulatory Application for Remplir™
Orthocell has today announced that the Company has submitted a regulatory application to the Health Services Authority of Singapore for approval to market and sell Remplir™ for use in peripheral nerve repair procedures
The Hon Kim Beazley AC Joins Orthocell Board
Orthocell has appointed Australia’s former US ambassador and Governor of Western Australia, The Hon Kim Beazley AC, as an Independent Non-Executive Director to the Board.
ABC News | Tennis elbow treatment trial successes offer hope for sufferers wary of surgery
This week, Orthocell was featured in a national news story (television, radio, online) about OrthoATI™ on ABC News.
Positive clinical results for OrthoATI™
Orthocell has today released positive results from our clinical study comparing OrthoATI™ to surgery for the treatment of severe chronic lateral epicondylitis (LE) – also known as tennis elbow.
Professor Fiona Wood AM joins Orthocell Board
Orthocell has today announced the appointment of one of Australia’s most innovative and respected plastic and reconstructive surgeons and researchers, Professor Fiona Wood AM, as an independent Non-Executive Director.
Quarterly Report – Period To 30 September 2023
Orthocell has today published its Quarterly Report for the period ended 30 September 2023.